Comparison of efficacy and safety of topical tacrolimus vs. narrowband ultraviolet B for moderate-severe atopic eczema
DOI:
https://doi.org/10.66344/jpad.33.2.2023.2528Keywords:
Atopic dermatitis; Topical tacrolimus; NB UVBAbstract
Objective To compare the efficacy and safety of topical tacrolimus with narrowband ultraviolet B for moderate-severe atopic eczema.
Methods 60 subjects, equally divided into Group A and B with the former treated with topical tacrolimus and the latter received narrowband ultraviolet B (NB UVB). These patients were followed up at 2, 4, 6, 8 and 12th weeks. Efficacy and side effects of the given treatment were recorded at each visit.
Results 90% of patients receiving NB UVB showed ≥50% SCORAD reduction as compared to 50% of cases applying tacrolimus. Fewer patients (60%) on NB UVB had side effects as compared to 66% of tacrolimus patients.
Conclusion NB UVB is a more effective and safer therapy than topical tacrolimus in moderate-severe atopic dermatitis in our patients.
Downloads
Published
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
